An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Moderate Hepatic Impairment.

Trial Profile

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Moderate Hepatic Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 27 Jul 2017 Results of a post-hoc pooled analysis of safety data from NCT00957684, NCT00957047, NCT00957372 NCT00988429, NCT02281422, NCT02281526 and NCT01422720 studies published in the Drug Safety
    • 06 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top